Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Alteplase for acute MI)
444 results
  • Changing Trends in Demographics, Risk Factors, and Clinical Features of Patients With Infective Endocarditis-Related Stroke, 2005-2015. [Journal Article]
    Neurology. 2023 Feb 06 [Online ahead of print]Ridha M, Flaherty ML, … Kleindorfer DO
  • CONCLUSIONS: From 2005 to 2015, infective endocarditis-related stroke was increasingly associated with intravenous drug use and fewer risk factors, specifically hypertension. These trends likely reflect the demographics of the opioid epidemic, which has affected younger patients with fewer comorbidities.Non-standard Abbreviations and Acronyms IERS: infective endocarditis-related stroke; IVDU: intravenous drug users; GCNKSS: Greater Cincinnati Northern Kentucky Stroke Study; NIHSS: National Institute of Health Stroke Scale; tPA: tissue plasminogen activator.
  • In vitro study about prevention of vascular reocclusion by low intensity ultrasonic irradiation. [Journal Article]
    Drug Discov Ther. 2022 Nov 20; 16(5):233-239.Sawaguchi Y, Wang Z, … Nakata N
  • For the treatment of acute ischemic stroke, the current standard of care is thrombolysis by the administration of intravenous (IV) recombinant tissue-type plasminogen activator (rt-PA). Although this approach is proven to be effective, reocclusion within 24 hours occurs in about 20% of patients who receive recanalization by rt-PA. In addition, the administration of anticoagulants within 24 hours …
  • Circadian rhythm and risk of hemorrhagic transformation after acute ischemic stroke treated with intravenous thrombolysis - a systematic review. [Journal Article]
    CNS Neurol Disord Drug Targets. 2022 Oct 04 [Online ahead of print]Stan A, Dragos H, … Muresanu DF
  • CONCLUSIONS: ICH occurred after ivT seems to follow a circadian pattern; the 18:00-00:00 time frame was the safest one, patients with AIS onset or ivT time between these hours had the lowest incidence of any ICH, including sICH. The 06:00-12:00 block was associated with the highest incidence of ICH and sICH. However, the analysis is limited by the small number of included studies and the heterogeneous findings reported. Further homogenized studies using comparable time frames and sICH definitions are needed to demonstrate this circadian pattern. The review protocol was registered in the OSF database under reference UHNF, doi:10.17605/OSF.IO/UHNF6.
  • Gene expression of fibrinolytic markers in coronary thrombi. [Journal Article]
    Thromb J. 2022 Apr 29; 20(1):23.Nordeng J, Solheim S, … Seljeflot I
  • CONCLUSIONS: Genes encoding tPA, uPA, PAI-1 and PAI-2 were highly expressed in human coronary thrombi from STEMI patients, indicating fibrinolytic regulators playing active roles in the thrombi, although not related to myocardial injury. All markers related to the presence of monocytes/macrophages, indicating connection to local inflammatory cells.
  • Endovascular Therapy for Acute Stroke with a Large Ischemic Region. [Randomized Controlled Trial]
    N Engl J Med. 2022 04 07; 386(14):1303-1313.Yoshimura S, Sakai N, … Morimoto T
  • CONCLUSIONS: In a trial conducted in Japan, patients with large cerebral infarctions had better functional outcomes with endovascular therapy than with medical care alone but had more intracranial hemorrhages. (Funded by Mihara Cerebrovascular Disorder Research Promotion Fund and the Japanese Society for Neuroendovascular Therapy; RESCUE-Japan LIMIT ClinicalTrials.gov number, NCT03702413.).
  • Overview of Acute Ischemic Stroke Evaluation and Management. [Review]
    Biomedicines. 2021 Oct 16; 9(10)Hasan TF, Hasan H, Kelley RE
  • Stroke is a major contributor to death and disability worldwide. Prior to modern therapy, post-stroke mortality was approximately 10% in the acute period, with nearly one-half of the patients developing moderate-to-severe disability. The most fundamental aspect of acute stroke management is "time is brain". In acute ischemic stroke, the primary therapeutic goal of reperfusion therapy, including i…
  • Door-In-Door-Out Process Times at Primary Stroke Centers in Chicago. [Multicenter Study]
    Ann Emerg Med. 2021 11; 78(5):674-681.Prabhakaran S, Khorzad R, … Holl JL
  • CONCLUSIONS: Door-in-door-out times at Chicago-area primary stroke centers average nearly 150 minutes. Reducing time to CT angiography, receipt of alteplase, and ambulance request are likely important modifiable targets for interventions to decrease door-in-door-out times at primary stroke centers.
  • COVID-19 and Acute Coronary Syndromes: From Pathophysiology to Clinical Perspectives. [Review]
    Oxid Med Cell Longev. 2021; 2021:4936571.Esposito L, Cancro FP, … Galasso G
  • Acute coronary syndromes (ACS) are frequently reported in patients with coronavirus disease 2019 (COVID-19) and may impact patient clinical course and mortality. Although the underlying pathogenesis remains unclear, several potential mechanisms have been hypothesized, including oxygen supply/demand imbalance, direct viral cellular damage, systemic inflammatory response with cytokine-mediated inju…
  • Paradoxical Myocardial Infarction After Thrombolytic Therapy for Acute Ischemic Stroke. [Case Reports]
    Cureus. 2021 Jul; 13(7):e16659.Mohmand B, Naqvi A, Singh A
  • Early reperfusion therapy with tissue plasminogen activator (tPA) for acute ischemic stroke has mortality benefits despite the risks. Myocardial infarction (MI) after the use of thrombolytic therapy is a rare complication. We report a 67-year-old woman with acute stroke who received tPA for acute ischemic stroke and subsequently developed ST elevation MI (STEMI), highlighting a rare and serious c…
  • Mechanisms of immunothrombosis in COVID-19. [Review]
    Curr Opin Hematol. 2021 11 01; 28(6):445-453.Portier I, Campbell RA, Denorme F
  • Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2. Over the past year, COVID-19 has posed a significant threat to global health. Although the infection is associated with mild symptoms in many patients, a significant proportion of patients develop a prothrombotic state due to a combination of alterations in coagulation and immun…
  • Pediatric Stroke: Overview and Recent Updates. [Review]
    Aging Dis. 2021 Jul; 12(4):1043-1055.Hollist M, Au K, … Kirmani BF
  • Stroke can occur at any age or stage in life. Although it is commonly thought of as a disease amongst the elderly, it is important to highlight the fact that it also affects infants and children. In both populations, strokes have a high rate of morbidity and mortality. Arguably, it is more detrimental in the pediatric population given the occurrence at a younger age and therefore, a longer durati…
  • Acute Stroke Management: Overview and Recent Updates. [Review]
    Aging Dis. 2021 Jul; 12(4):1000-1009.Hollist M, Morgan L, … Kirmani BF
  • Stroke is a leading cause of morbidity and mortality in the United States. Whether hemorrhagic or ischemic, stroke leads to severe long-term disability. Prior to the mid-1990s, the treatment offered to a patient who presented with an acute stroke was mainly limited to antiplatelets. The lack of adequate treatment, in particular, one without reperfusion contributed to the disability that ensued. T…
  • Age and Acute Ischemic Stroke Outcome in North American Patients With COVID-19. [Journal Article]
    J Am Heart Assoc. 2021 07 20; 10(14):e021046.Dmytriw AA, Dibas M, … North American Neurovascular COVID‐19 (NAN‐C) Consortium
  • Background Acute ischemic stroke (AIS) in the context of COVID-19 has received considerable attention for its propensity to affect patients of all ages. We aimed to evaluate the effect of age on functional outcome and mortality following an acute ischemic event. Methods and Results A prospectively maintained database from comprehensive stroke centers in Canada and the United States was analyzed f…
  • Bone marrow-derived NCS-01 cells for ischemic stroke. [Review]
    Brain Circ. 2021 Jan-Mar; 7(1):44-47.Saft M, Koga M, Borlongan CV
  • Stroke stands as one of the most common causes of death among adults worldwide. Currently, tissue plasminogen activator serves as the only approved drug by the Food and Drug Administration for the treatment of acute ischemic stroke. Stem cell therapy serves as a viable treatment option and has been deemed as a safe and effective treatment for stroke patients. Adult human bone marrow-derived NCS-0…
New Search Next